MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria CEO Hoffman Most Cited Author in the World
Essential Scientific Indicators has reported that Dr. Stephen L. Hoffman, Founder and Chief Executive Officer of Sanaria Inc., is the most cited author in the world for scientific papers on malaria published between 1995 and 2005.
Rockville’s Sanaria to test malaria vaccine
While Sanaria Inc. works to keep its focus on developing revenue streams, the estimated 3,000 children who die each day in a global resurgence of malaria add a humanitarian perspective for the Rockville company. This week, Sanaria, headed by CEO Stephen Hoffman, begins manufacturing its first run of a unique and promising malaria vaccine.
The Malaria Fighter
Sanaria's Dr. Hoffman is featured in Business 2.0 magazine's The Smart List edition.
An Interview with Dr. Stephen Hoffman
In Essential Science Indicators, Dr. Hoffman’s work can be found in the fields of Immunology and Microbiology. Dr. Hoffman is the founder, CEO, and Chief Scientific Officer of Sanaria, Inc. in Rockville, Maryland. In the interview below, he talks with Special Topics correspondent Gary Taubes about his highly cited work in malaria research.
Sanaria Inc. Receives Multi-Year $3 Million U.S. NIH Phase II Small Business Innovation Research Grant for Further Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine, announced the receipt of a multi-year Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Sanaria Inc. Receives U.S. Army Award for Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine announced the receipt of a $4.09 million research and development award from the United States Army Medical Research Acquisition Activity Group in Fort Detrick, Maryland.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.